Editas Medicine to Present at Upcoming February Investor Conferences
February 10, 2017 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will present a company overview at two...
Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference
January 09, 2017 08:00 ET
|
Editas Medicine
- Company Achieves In Vivo Proof-of-Editing in the Retina of Non-Human Primates - - Unparalleled Genome Editing Platform Includes Cpf1 and...
Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 04, 2017 08:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas Medicine Extends CRISPR Genome Editing Leadership Through Licensing of New CRISPR Technologies
December 19, 2016 07:00 ET
|
Editas Medicine
-- Company to Receive Global Licenses for Novel CRISPR System Cpf1 and Advanced Forms of Cas9 --CAMBRIDGE, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading...
Editas Medicine to Present at the Stifel Healthcare Conference 2016
November 09, 2016 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the Stifel...
Editas Medicine Announces Third Quarter 2016 Results and Update
November 07, 2016 16:01 ET
|
Editas Medicine
Further strengthened leadership team with appointments of Charles Albright, Ph.D., as Chief Scientific Officer, and Gerald Cox, M.D., Ph.D., as Chief Medical Officer CAMBRIDGE, Mass., Nov. 07,...
Editas Medicine to Host Conference Call Discussing Third Quarter 2016 Corporate Update and Results
October 31, 2016 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine to Present Data on CRISPR/Cas9-mediated Gene Editing in Hematopoietic Stem/Progenitor Cells at ESGCT-ISSCR 2016
October 17, 2016 07:30 ET
|
Editas Medicine
CAMBRIDGE, Mass., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that its scientists will present data on the use of...
Editas Medicine Reports Inducement Grant to New Chief Medical Officer
October 06, 2016 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the grant of an inducement award to the company’s newly...
Editas Medicine to Present at the Jefferies Gene Editing/Therapy Summit
October 03, 2016 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it will present at 9:00 a.m. ET and participate in a...